Feeds › Capitol Hires
Capitol Hires
Lobbyists whose filings say they once worked in a member of Congress' office, on a committee or in the executive branch, with the public company that hired them.
About this data
- What it is
- Capitol Hires lists lobbyists who say, in a filing under the Lobbying Disclosure Act, that they once held a government job: in a member of Congress’ office, on a congressional committee or in the executive branch. Each row names the public company that hired the lobbyist (directly or through a lobbying firm), the office they came from and the job they held there.
- Who files it
- The lobbying firm (or the company, for its own lobbyists) on each quarterly report (LD-2) and registration (LD-1) it files with the Senate and the House.
- How current
- New filings are posted every day. We read each one the day after it is posted.
- Terms
- Covered positionA covered position is a job in the federal government that a lobbyist held in the 20 years before the filing: in the office of a member of Congress, on a committee, or in the executive branch. The Lobbying Disclosure Act asks the lobbyist to name it.As writtenThe office, the member and the job title are shown as the registrant typed them. A short job title such as LD or CoS is not spelled out.Linked memberA member is linked to their page only when exactly one member of Congress fits the name, the chamber, the first name and the years given. Otherwise the name is shown as written, without a link.FilingsThe same lobbyist is usually named again on each quarterly report for the same client. A row is shown once, with the number of filings that name them for this client and the latest one.
- Worth knowing
- Each row reflects what was disclosed at the time of filing. A lobbyist listed may no longer be registered. The text is free-form, so we read it by rules and some offices are missed or misread. Check the filing before relying on one row. A member is linked only on a unique match, and many are not: those are shown as written. Company matching is automatic and can miss a subsidiary. Information, not investment advice.
All of this comes from lobbying disclosure filings that the Senate and the House publish.
Information, not investment advice (disclaimer). Where this data comes from.
Latest Capitol Hires
| The covered position the lobbyist says they held: an office of a member of Congress, a committee or an executive-branch body, as written in the filing. The member's name is a link only when exactly one member of Congress fits the name, chamber, first name and years given; otherwise it stays as written. | The lobbying report (LDA form LD-2) that names this lobbyist and office, with a link to it. Report period is the quarter the report covers; Posted is the day it was filed or amended, which can be much later. The same lobbyist is named again on each quarterly report for the same client, so a row is shown once, from the newest report, with the number of filings that name them. | ||||
|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | Steven Crane | Barbara A. Mikulski Member office · Democrat-MD | Staff assistant | Crane Strategies | Report period 2026 Q3 ↗ Posted Nov 3, 2026 · in 8 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Brent del Monte | Bliley (House) Member office · House | Leg. Dir | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 7 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Brent del Monte | Commerce Committee Committee | Sen. Counsel House Energy | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 7 filings |
| REGN Regeneron Pharmaceuticals, Inc. | John Stone | Oversight Subcommittee Committee | Counsel | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 4 filings |
| REGN Regeneron Pharmaceuticals, Inc. | John Stone | House E&C Cmte Committee | Senior Counsel | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 4 filings |
| REGN Regeneron Pharmaceuticals, Inc. | John Stone | Health Subcommittee Committee | Senior Counsel | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 4 filings |
| REGN Regeneron Pharmaceuticals, Inc. | John Stone | House Energy and Commerce Committee | Intern | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 4 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Daniel Farmer | Debbie Wasserman Schultz Member office · Democrat-FL | Intern, Staff Asst, Leg. Corr./Leg. Asst | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 4 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Daniel Farmer | Zack Space Member office | Leg. Asst., Sr. Leg. Asst., Leg. Dir | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 4 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Remy Mason | Senate HELP Committee Committee | Senior FDA Policy Advisor to Ranking Member Patty Murray | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 4 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Remy Mason | Elizabeth Warren Member office · Democrat-MA | Senior Health Policy Advisor | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 4 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Remy Mason | Allyson Y. Schwartz Member office · Democrat-PA | Intern | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 4 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Raghav Aggarwal | Senate Finance Committee Committee | Senior Health Advisor | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 7 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Raghav Aggarwal | Detailee (Senate) Member office · Senate | Senior Health Advisor | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 7 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Raghav Aggarwal | Ron Wyden Member office · Democrat-OR | Not stated | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 7 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Raghav Aggarwal | CMS Executive branch | Social Science Research Analyst | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 7 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Raghav Aggarwal | Feinstein (Senate) Member office · Senate | Intern | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 7 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Raghav Aggarwal | US Dept. of Interior Executive branch | Secretarys Fellow | BGR Government Affairs | Report period 2026 Q3 ↗ Posted Oct 20, 2026 · in 7 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Timothy Blanchat | Richard Hudson Member office · Republican-NC | Chief of Staff | Checkmate Government Relations | Report period 2026 Q3 ↗ Posted Oct 16, 2026 · in 2 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Timothy Blanchat | Thom Tillis Member office · Republican-NC | Deputy State Director | Checkmate Government Relations | Report period 2026 Q3 ↗ Posted Oct 16, 2026 · in 2 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Sam Holland | Department of Treasury Executive branch | Not stated | Checkmate Government Relations | Report period 2026 Q3 ↗ Posted Oct 16, 2026 |
| REGN Regeneron Pharmaceuticals, Inc. | Sam Holland | National Security Council Executive branch | Not stated | Checkmate Government Relations | Report period 2026 Q3 ↗ Posted Oct 16, 2026 |
| REGN Regeneron Pharmaceuticals, Inc. | Gregory Nickerson | Ways and Means Committee Committee | Tax Counsel | The Washington Tax & Public Policy Group | Report period 2026 Q3 ↗ Posted Oct 15, 2026 · in 8 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Gregory Nickerson | Ways and Means Select Revenue Measures Subcommittee Committee | Staff Director | The Washington Tax & Public Policy Group | Report period 2026 Q3 ↗ Posted Oct 15, 2026 · in 8 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Zachary Price | Coats (Senate) Member office · Senate | Staff assistant | The Washington Tax & Public Policy Group | Report period 2026 Q3 ↗ Posted Oct 15, 2026 · in 7 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Frederick Vaughan | Treasury Dept. Executive branch | Deputy Asst. Secretary | Checkmate Government Relations | Report period 2025 Q4 ↗ Posted Jan 20, 2026 · in 5 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Frederick Vaughan | House Financial Services Cmte Committee | Senior Counsel | Checkmate Government Relations | Report period 2025 Q4 ↗ Posted Jan 20, 2026 · in 5 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Frederick Vaughan | Office of Management & Budget Executive branch | Confidential Asst | Checkmate Government Relations | Report period 2025 Q4 ↗ Posted Jan 20, 2026 · in 5 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Frederick Vaughan | White House Executive branch | Writer | Checkmate Government Relations | Report period 2025 Q4 ↗ Posted Jan 20, 2026 · in 5 filings |
| REGN Regeneron Pharmaceuticals, Inc. | Zachary Price | Daniel Coats Member office · Republican-IN | Staff Assistant | The Washington Tax & Public Policy Group | Report period 2025 Q1 ↗ Posted Feb 7, 2025 |
| REGN Regeneron Pharmaceuticals, Inc. | James Pedrotti | Carol D. Miller Member office · Republican-WV | Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Deputy Chief of Staff | The Washington Tax & Public Policy Group | Report period 2025 Q1 ↗ Posted Feb 7, 2025 |
The newest 31 of 31 matching. Narrow them with the filters above.
Each row reflects what was disclosed at the time of filing. A lobbyist listed may no longer be registered. The same lobbyist is usually named again on each quarterly report for the same client. A row is shown once, with the number of filings that name them for this client and the latest one. Updated Nov 15, 2026, 6:22 PM EST.